{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-23-000065","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.605986+00:00","generated_at":"2026-06-08T05:08:37.263203+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acumen updates ACU193 Phase 1 subcutaneous trial to mid-2024; secures $50M credit facility","bullets":["Projected mid-2024 initiation of Phase 1 subcutaneous trial for ACU193.","Reported results from recent FDA interaction regarding ACU193 development.","Additional CSF biomarker data from Phase 1 INTERCEPT-AD trial presented.","New credit facility of up to $50 million from K2 HealthVentures."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-23-000065","json":"https://secwatch.observer/filing/0001576885-23-000065.json","markdown":"https://secwatch.observer/filing/0001576885-23-000065.md","text":"https://secwatch.observer/filing/0001576885-23-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000065/0001576885-23-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000065/abos-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:08:37.263203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}